Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Summary of findings: bevacizumab vs ranibizumab

Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.51 [0.05, 5.62]
1670 participants
Moderate

Summary of findings: bevacizumab vs ranibizumab

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1.15 [0.99, 1.34]
6 studies · 3365 participants
Moderate